Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients.
COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0309449 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849303630982676480 |
|---|---|
| author | Carlo J Iasella Stefanie J Hannan Emily J Lyons Sophia C Lieber Antu Das Dimiter Dimitrov Wei Li Melissa Saul Iulia Popescu Ritchie Koshy Robin Burke Braidon Lape Mark J Brown Xiaoping Chen John C Sembrat Kaitlyn Devonshire Georgios D Kitsios Ioannis Konstantinidis Mark E Snyder Bill B Chen Christian A Merlo David N Hager Joseph E Kiss Mark H Yazer Alan H Wells Alison Morris Bryan J McVerry Deborah K McMahon Darrell J Triulzi John F McDyer |
| author_facet | Carlo J Iasella Stefanie J Hannan Emily J Lyons Sophia C Lieber Antu Das Dimiter Dimitrov Wei Li Melissa Saul Iulia Popescu Ritchie Koshy Robin Burke Braidon Lape Mark J Brown Xiaoping Chen John C Sembrat Kaitlyn Devonshire Georgios D Kitsios Ioannis Konstantinidis Mark E Snyder Bill B Chen Christian A Merlo David N Hager Joseph E Kiss Mark H Yazer Alan H Wells Alison Morris Bryan J McVerry Deborah K McMahon Darrell J Triulzi John F McDyer |
| author_sort | Carlo J Iasella |
| collection | DOAJ |
| description | COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of antibodies in the administered CCP influenced clinical effectiveness. In an inpatient population within a single large health system, a total of 290 CCP patients were matched to 290 controls. While CCP increased titers of anti-SARS-CoV-2 RBD IgG titers post-CCP (p = <0.0001), no differences in 30-day survival were observed between CCP patients and controls in univariate and multivariate analyses. Survival at 30 days was numerically lower in recipients who were seronegative prior to CCP administration, compared to those with low titer and high titer anti-SARS-CoV-2 RBD IgG, respectively, but did not reach statistical significance (56% vs 82% vs 75%, p = 0.16). Patients who received 2 units of high-titer CCP had numerically better survival versus those who received fewer high-titer units, but this was not statistically significant (p = 0.08). CCP did not improve 30-day survival compared to propensity matched controls. Together these data support that CCP therapy provides limited benefit to hospitalized patients with SARS-CoV-2 infection. |
| format | Article |
| id | doaj-art-1c4ef69de9fc4199aaa389d89af3a908 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-1c4ef69de9fc4199aaa389d89af3a9082025-08-20T03:56:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-011910e030944910.1371/journal.pone.0309449Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients.Carlo J IasellaStefanie J HannanEmily J LyonsSophia C LieberAntu DasDimiter DimitrovWei LiMelissa SaulIulia PopescuRitchie KoshyRobin BurkeBraidon LapeMark J BrownXiaoping ChenJohn C SembratKaitlyn DevonshireGeorgios D KitsiosIoannis KonstantinidisMark E SnyderBill B ChenChristian A MerloDavid N HagerJoseph E KissMark H YazerAlan H WellsAlison MorrisBryan J McVerryDeborah K McMahonDarrell J TriulziJohn F McDyerCOVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of antibodies in the administered CCP influenced clinical effectiveness. In an inpatient population within a single large health system, a total of 290 CCP patients were matched to 290 controls. While CCP increased titers of anti-SARS-CoV-2 RBD IgG titers post-CCP (p = <0.0001), no differences in 30-day survival were observed between CCP patients and controls in univariate and multivariate analyses. Survival at 30 days was numerically lower in recipients who were seronegative prior to CCP administration, compared to those with low titer and high titer anti-SARS-CoV-2 RBD IgG, respectively, but did not reach statistical significance (56% vs 82% vs 75%, p = 0.16). Patients who received 2 units of high-titer CCP had numerically better survival versus those who received fewer high-titer units, but this was not statistically significant (p = 0.08). CCP did not improve 30-day survival compared to propensity matched controls. Together these data support that CCP therapy provides limited benefit to hospitalized patients with SARS-CoV-2 infection.https://doi.org/10.1371/journal.pone.0309449 |
| spellingShingle | Carlo J Iasella Stefanie J Hannan Emily J Lyons Sophia C Lieber Antu Das Dimiter Dimitrov Wei Li Melissa Saul Iulia Popescu Ritchie Koshy Robin Burke Braidon Lape Mark J Brown Xiaoping Chen John C Sembrat Kaitlyn Devonshire Georgios D Kitsios Ioannis Konstantinidis Mark E Snyder Bill B Chen Christian A Merlo David N Hager Joseph E Kiss Mark H Yazer Alan H Wells Alison Morris Bryan J McVerry Deborah K McMahon Darrell J Triulzi John F McDyer Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients. PLoS ONE |
| title | Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients. |
| title_full | Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients. |
| title_fullStr | Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients. |
| title_full_unstemmed | Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients. |
| title_short | Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients. |
| title_sort | impact of variable titer covid 19 convalescent plasma and recipient sars cov2 specific humoral immunity on survival in hospitalized patients |
| url | https://doi.org/10.1371/journal.pone.0309449 |
| work_keys_str_mv | AT carlojiasella impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT stefaniejhannan impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT emilyjlyons impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT sophiaclieber impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT antudas impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT dimiterdimitrov impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT weili impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT melissasaul impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT iuliapopescu impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT ritchiekoshy impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT robinburke impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT braidonlape impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT markjbrown impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT xiaopingchen impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT johncsembrat impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT kaitlyndevonshire impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT georgiosdkitsios impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT ioanniskonstantinidis impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT markesnyder impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT billbchen impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT christianamerlo impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT davidnhager impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT josephekiss impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT markhyazer impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT alanhwells impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT alisonmorris impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT bryanjmcverry impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT deborahkmcmahon impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT darrelljtriulzi impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients AT johnfmcdyer impactofvariabletitercovid19convalescentplasmaandrecipientsarscov2specifichumoralimmunityonsurvivalinhospitalizedpatients |